Ilumin8bio

ilumin8bio is a leader in precision cancer therapies, creating first-in-class solutions using next-generation antibody conjugation technologies to improve therapeutic efficacy while reducing toxicity. We specialize in advanced linker chemistry and solid-phase synthesis platforms for both Antibody-Drug Conjugates (ADCs) and Targeted Radionuclide Therapies (TRTs). Our proprietary solid-phase synthesis approach enables homogeneous drug-to-antibody ratios, multi-payload loading capabilities, and site-specific conjugation—addressing critical limitations in current cancer treatments. Our expertise in solid-phase synthesis creates simplified manufacturing processes that simultaneously increase yield, efficiency, quality, and safety while reducing costs. This breakthrough approach helps biotechnology and pharmaceutical companies overcome the conjugation bottlenecks that have limited the success of targeted cancer therapies. Through our innovative linker platforms, we're transforming how precision oncology treatments are designed, manufactured, and delivered to patients who need them most.